SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

ebribafusp alfa

AKBA·Akebia Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
Ebribafusp is in Phase 2 testing with initial data expected in 2027. If Phase 2 results are positive, Phase 3 trials would be needed before any regulatory filing, putting potential approval several years away (likely 2029 or later under an optimistic scenario).
Why 4/10
The next catalyst is initial Phase 2 basket trial data expected in 2027 (no specific month announced), which is more than 6 months out. Ebribafusp is a mid-stage pipeline asset at a company that already has a commercial product (Vafseo) and other pipeline programs, so this single drug is not a make-or-break binary for the stock in the near term.
Actionable Insight NEUTRAL

The next catalyst is initial Phase 2 basket trial data, expected in 2027 (no specific month announced). Positive data would validate ebribafusp's tissue-targeted complement inhibition approach across three rare kidney diseases and could significantly increase the asset's value. Negative or equivocal data would likely reduce the pipeline's perceived value, though Akebia's commercial product Vafseo provides a revenue floor that limits downside relative to a pure single-asset developer.

Price Chart

Loading chart...

Executive Summary

Ebribafusp alfa (AKB-097, formerly ADX-097) is an investigational, tissue-targeted complement inhibitor being developed by Akebia Therapeutics (Nasdaq: AKBA) for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Akebia acquired global rights from Q32 Bio in December 2025 for $7M upfront. The drug completed Phase 1 testing in healthy volunteers and entered a Phase 2 open-label basket trial in August 2026 (first patient dosed September 2026), enrolling up to 30 patients with once-weekly subcutaneous dosing. Initial data is expected in 2027. Ebribafusp is one of several mid-stage pipeline assets at Akebia, which also markets the approved anemia drug Vafseo (vadadustat). The stock trades near $0.41 with a strong analyst consensus (10 Buy/Strong Buy ratings, mean price target $3.92) but faces Nasdaq minimum bid price compliance issues.

How It Works

Ebribafusp alfa is a fusion protein that works like a smart bomb for the immune system's complement cascade (a part of the body's defense that can cause inflammation and tissue damage). It targets a protein fragment called C3d that builds up in the kidneys of patients with certain rare kidney diseases. Once it latches onto C3d, it delivers a natural complement inhibitor (factor H) directly to the site of damage, turning off the destructive inflammation locally without suppressing the entire complement system throughout the body. This tissue-targeted approach is designed to reduce the risk of serious bacterial infections that can occur with systemic complement inhibitors.

Trial Status

A Phase 2 open-label basket trial (NCT06419205) was initiated in August 2026, with the first patient dosed in September 2026. The trial is enrolling up to 30 patients with IgA nephropathy, lupus nephritis, or C3 glomerulopathy, evaluating once-weekly subcutaneous dosing for 26 weeks with a long-term extension for responders. A Phase 1 trial in healthy volunteers (conducted by Q32 Bio) was completed and showed the drug was generally well-tolerated with minimal anti-drug antibodies.

The Two-Sided Case

▲ Bull Case5
Ebribafusp's tissue-targeted mechanism (delivering factor H locally to C3d deposits without systemic complement suppression) could offer a safety advantage over systemic complement inhibitors, potentially reducing serious infection risk.
Phase 1 data in healthy volunteers showed the drug was generally well-tolerated with minimal anti-drug antibodies, and weekly 450 mg SC dosing achieved desired exposures for predicted tissue complement inhibition.
Akebia acquired global rights from Q32 Bio for a modest $7M upfront plus up to $12M in milestones, giving it a potentially high-upside pipeline asset at low cost.
The company has a commercial product (Vafseo/vadadustat) generating revenue with 140% year-over-year patient growth, plus $159.3M in cash to fund pipeline development through initial data.
Analyst consensus is strongly bullish: 10 analysts rate the stock Buy or Strong Buy (none rate Sell), with a mean price target of $3.92 versus the current ~$0.41 price, implying over 800% upside.
▼ Bear Case5
The Phase 2 basket trial is early-stage (30 patients, open-label) and initial data is not expected until 2027, meaning no near-term catalyst to drive the stock.
The complement inhibitor space for IgA nephropathy is increasingly crowded: iptacopan (Novartis) is already approved, and other competitors like ravulizumab and sefaxersen are in development, raising the bar for differentiation.
Akebia's stock trades near $0.40, well below the Nasdaq minimum bid price of $1.00, and the company received a Nasdaq deficiency notice in October 2026, creating potential delisting risk.
Several large institutional holders trimmed or exited AKBA positions in Q2 2026, including State Street (trimmed 54%), Bank of America (near-exit), and Citigroup (trimmed 61%), signaling mixed conviction.
Total revenue fell 37% YoY in Q3 2026 to $36.9M, driven by generic competition to Auryxia, and the company posted a $14.4M net loss.

Upcoming Catalysts

  • Initial Phase 2 basket trial data readout (expected in 2027, no specific date announced)
  • ASN Kidney Week or other medical conference presentations of preclinical or early clinical data
  • Potential partnership or licensing updates for the rare kidney disease pipeline

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Akebia Therapeutics, Inc. PRESS-RELEASE AKBA ·Originating report

Sources · 10

Hover a chip for the title
1 ir.akebia.com2 biospace.com3 biospace.com4 ir.akebia.com5 ir.q32bio.com6 adisinsight.springer.com7 fiercebiotech.com8 akebia.com9 asn-online.org10 clinicaltrials.gov